Please check your internet connection and try again.
# Urimax (tamsulosin)
## Overview
Tamsulosin is a selective α1A-adrenoceptor antagonist that relaxes smooth muscle in the bladder neck and prostate. It is structurally selective for the prostate rather than the vasculature, reducing the risk of systemic hypotension compared to non-selective alpha-blockers.
## Primary Indications
* Treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
* *Off-label:* Medical expulsive therapy for ureteral stones; treatment of lower urinary tract symptoms (LUTS) in women (uncommon).
## Adult Dosing
* **Standard Dose:** 0.4 mg orally once daily.
* **Maximum Dose:** 0.8 mg orally once daily. If no improvement is seen with 0.4 mg after 2–4 weeks, the dose may be increased to 0.8 mg daily.
* **Administration:** Administer approximately 30 minutes after the same meal each day. Do not crush or chew capsules.
## Pediatric Dosing
Tamsulosin is not indicated for pediatric use. Safety and efficacy in children have not been established.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment is required for mild to moderate impairment. Use caution in severe renal impairment (CrCl <10 mL/min).
* **Hepatic Impairment:** No dosage adjustment indicated for mild to moderate impairment. Use is not recommended in severe hepatic impairment.
* **CYP3A4/2D6 Inhibitors:** Avoid use with strong inhibitors (e.g., ketoconazole, clarithromycin). Use caution with moderate inhibitors.
## Contraindications
* Hypersensitivity to tamsulosin or any component of the formulation.
## Adverse Effects
* **Common:** Orthostatic hypotension (though less frequent than with non-selective agents), dizziness, headache, abnormal ejaculation (ejaculatory dysfunction).
* **Serious:** Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, priapism, syncope.
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors (e.g., Ketoconazole):** May significantly increase plasma concentrations of tamsulosin.
* **PDE5 Inhibitors (e.g., Sildenafil, Tadalafil):** Use with caution due to the risk of additive blood pressure lowering effects.
* **Other Antihypertensives:** Potential for additive hypotensive effects.
## Monitoring
* Monitor blood pressure during the initiation of therapy to assess for orthostatic hypotension.
* Evaluate urinary symptoms at follow-up visits to assess therapeutic response.
* Screen for history of cataract surgery or upcoming ocular procedures.
## Clinical Pearls
* **Cataract Surgery:** Advise patients to inform their ophthalmologist of current or prior tamsulosin use, as it significantly increases the risk of IFIS.
* **Administration Timing:** Taking the medication without food, or with different meals, may result in variable absorption and increased risk of side effects.
* **Ejaculatory Dysfunction:** Counsel patients on the high prevalence of retrograde ejaculation; this is a common cause of treatment discontinuation.
* **Onset:** Clinical improvement is often observed within one week, but may take several weeks for maximal effect.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical guidelines and prescribing information change frequently. Always consult the most recent product monograph, electronic prescribing resources (e.g., Lexicomp, UpToDate), or local institutional protocols before prescribing or administering medication.
